HUTCHMED (China) Limited announced that Dr. Renu Bhatia is appointed as an Independent Non-executive Director and a member of Technical Committee of the Company with effect from May 13, 2024. Dr. Bhatia, a licensed physician, has over 25 years of experience in the healthcare, finance and fintech, and regulatory sectors. She is an experienced board director and chair, with a healthcare and financial services background in investment banking, asset management, venture capital and compliance.

The Board of HUTCHMED is of the view that Dr. Bhatia will further enhance the skill set, expertise and knowledge base of the Board as a whole. Dr. Bhatia, aged 65, is the chairman and co-founder of Opharmic Technology (HK) Ltd, a company focusing on the development of ultrasound technology for non-invasive Dr.ug delivery to the eyes. She is also co-founder of Asia Fintech Angels which invested in early stage fintech companies.

In addition, Dr. Bhatia is an independent non-executive director of Overstone Associates Limited, a leading UK based data science provider to financial institutions focused on the art industry. Dr. Bhatia is the chairman of the Listing Committee of The Stock Exchange of Hong Kong Limited. She also holds positions in public service including membership of the Business Professional Federation Healthcare Committee and the Cyberport Entrepreneurship Centre Advisory Group, and acting as an assessor for the Hong Kong Enterprise Support Scheme Assessment Panel of the Innovation and Technology Fund.

Dr. Bhatia started her career in finance at Goldman Sachs and HSBC Asset Management. Dr. Bhatia is a Doctor of Medicine (MBBS) from the University of London and holds a Master of Business Administration degree from Yale University, and a Postgraduate Diploma in Therapeutics and Medicine from The University of Hong Kong. Dr. Bhatia has relevant board experience with the following private companies, currently holding or having held in the past five years the following directorships: Current Directorships: Opharmic Technology (HK) Limited; Overstone Associates Limited; Tancho Investments Limited.

Previous Directorships in the last five years: Asia Prism Ventures Limited; SuperCharger Limited. The initial term of the appointment of Dr. Bhatia as an Independent Non-executive Director of the Company shall end at the next following annual general meeting of the Company, subject to retirement in accordance with the Articles of Association of the Company and applicable legal and regulatory requirements, and thereafter for successive periods of 12 months, unless she is not re-elected at the next following annual general meeting or her appointment is otherwise terminated earlier by either party in writing.